newsfilter
← Latest News
GlobeNewswire·

HilleVax Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress

$159.5 million of cash, cash equivalents and marketable securities as of March 31, 2025 The company is exploring the potential for continued development of its norovirus vaccine candidates inadults as well as business